Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Sachin Sharma, Karan Wadhwa, Manjusha Choudhary & Vikas Budhwar. (2022) Ethnopharmacological perspectives of glucokinase activators in the treatment of diabetes mellitus. Natural Product Research 36:11, pages 2962-2976.
Read now
Read now
Kevin J Filipski & Jeffrey A Pfefferkorn. (2014) A patent review of glucokinase activators and disruptors of the glucokinase – glucokinase regulatory protein interaction: 2011 – 2014. Expert Opinion on Therapeutic Patents 24:8, pages 875-891.
Read now
Read now
Jeffrey A Pfefferkorn. (2013) Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes. Expert Opinion on Drug Discovery 8:3, pages 319-330.
Read now
Read now
Ramakanth Sarabu, Steven J Berthel, Robert F Kester & Jefferson W Tilley. (2011) Novel glucokinase activators: a patent review (2008 – 2010). Expert Opinion on Therapeutic Patents 21:1, pages 13-33.
Read now
Read now
Philip A Carpino & Bryan Goodwin. (2010) Diabetes area participation analysis: a review of companies and targets described in the 2008 – 2010 patent literature. Expert Opinion on Therapeutic Patents 20:12, pages 1627-1651.
Read now
Read now
Thomas D Aicher, Steven A Boyd, Maralee McVean & Anthony Celeste. (2010) Novel therapeutics and targets for the treatment of diabetes. Expert Review of Clinical Pharmacology 3:2, pages 209-229.
Read now
Read now
Jefferson W Tilley. (2009) Glucokinase activators: Novo Nordisk's WO2008084044 and Array Biopharma's WO2008091770. Expert Opinion on Therapeutic Patents 19:4, pages 549-553.
Read now
Read now
Articles from other publishers (43)
Prateek Sharma, Aman Thakur, Anju Goyal & Ajmer Singh Grewal. (2023) Molecular docking, 2D-QSAR and ADMET studies of 4-sulfonyl-2-pyridone heterocycle as a potential glucokinase activator. Results in Chemistry, pages 101105.
Crossref
Crossref
Ke Wang, Mai Shi, Chuiguo Huang, Baoqi Fan, Andrea O. Y. Luk, Alice P. S. Kong, Ronald C. W. Ma, Juliana C. N. Chan & Elaine Chow. (2022) Evaluating the impact of glucokinase activation on risk of cardiovascular disease: a Mendelian randomisation analysis. Cardiovascular Diabetology 21:1.
Crossref
Crossref
A.A. Kazi & V.A. Chatpalliwar. (2022) Design, Synthesis, Molecular Docking and In vitro Biological Evaluation of
Benzamide Derivatives as Novel Glucokinase Activators. Current Enzyme Inhibition 18:1, pages 61-75.
Crossref
Crossref
Ajinkya Chavan, Kratika Daniel & Ansar M. Patel. (2022) In-silico Exploration of Phytoconstituents of Gymnema sylvestre as Potential
Glucokinase Activators and DPP-IV Inhibitors for the Future Synthesis
of Silver Nanoparticles for the Treatment of Type 2 Diabetes Mellitus. Current Enzyme Inhibition 18:1, pages 47-60.
Crossref
Crossref
Altaf Khan, Aziz Unnisa, Mo Sohel, Mohan Date, Nayan Panpaliya, Shweta G. Saboo, Falak Siddiqui & Sharuk Khan. (2021) Investigation of phytoconstituents of Enicostemma littorale as potential glucokinase activators through molecular docking for the treatment of type 2 diabetes mellitus. In Silico Pharmacology 10:1.
Crossref
Crossref
Ajmer S. Grewal, Viney Lather, Neha Charaya, Neelam Sharma, Sukhbir Singh & Visvaldas Kairys. (2020) Recent Developments in Medicinal Chemistry of Allosteric Activators of Human Glucokinase for Type 2 Diabetes Mellitus Therapeutics. Current Pharmaceutical Design 26:21, pages 2510-2552.
Crossref
Crossref
V. Nurmaylindha, G. P. Widodo & R. Herowati. Molecular docking analysis of Leucaena leucocephala and Trigonella foenum-graecum chemical constituents on antidiabetic macromolecular targets and prediction of the pharmacokinetic profiles. Molecular docking analysis of Leucaena leucocephala and Trigonella foenum-graecum chemical constituents on antidiabetic macromolecular targets and prediction of the pharmacokinetic profiles.
Saurabh C. Khadse, Nikhil D. Amnerkar, Manasi U. Dave, Deepak K. Lokwani, Ravindra R. Patil, Vinod G. Ugale, Nitin B. Charbe & Vivekanand A. Chatpalliwar. (2019) Quinazolin-4-one derivatives lacking toxicity-producing attributes as glucokinase activators: design, synthesis, molecular docking, and in-silico ADMET prediction. Future Journal of Pharmaceutical Sciences 5:1.
Crossref
Crossref
Dalong Zhu, Shenglian Gan, Yu Liu, Jianhua Ma, Xiaolin Dong, Weihong Song, Jiao'e Zeng, Guixia Wang, Wenjuan Zhao, Qiu Zhang, Yukun Li, Hui Fang, Xiaofeng Lv, Yongquan Shi, Haoming Tian, Linong Ji, Xin Gao, Lihui Zhang, Yuqian Bao, Minxiang Lei, Ling Li, Longyi Zeng, Xiaoying Li, Xinghua Hou, Yu Zhao, Tianxin Hu, Xiaoyun Ge, Guiyu Zhao, Yongguo Li, Yi Zhang & Li Chen. (2018) Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: a dose-ranging, randomised, double-blind, placebo-controlled, phase 2 study. The Lancet Diabetes & Endocrinology 6:8, pages 627-636.
Crossref
Crossref
Nanda Kumar Yellapu, Ravendra Babu Kilaru, Nagaraju Chamarthi, Sarma PVGK & Bhaskar Matcha. (2017) Structure based design, synthesis and biological evaluation of amino phosphonate derivatives as human glucokinase activators. Computational Biology and Chemistry 68, pages 118-130.
Crossref
Crossref
Ruben Vardanyan & Victor Hruby. 2016. Synthesis of Best-Seller Drugs. Synthesis of Best-Seller Drugs
419
458
.
P. M. Rubtsov, E. L. Igudin & A. N. Tiulpakov. (2015) Glucokinase and glucokinase regulatory proteins as molecular targets for novel antidiabetic drugs. Molecular Biology 49:4, pages 494-499.
Crossref
Crossref
Ashish Radadiya & Anamik Shah. (2015) Bioactive benzofuran derivatives: An insight on lead developments, radioligands and advances of the last decade. European Journal of Medicinal Chemistry 97, pages 356-376.
Crossref
Crossref
Ronald J. Hinklin, Thomas D. Aicher, Deborah A. Anderson, Brian R. Baer, Steven A. Boyd, Kevin R. Condroski, Walter E. DeWolfJr.Jr., Christopher F. Kraser, Maralee McVean, Susan P. Rhodes, Hillary L. Sturgis, Walter C. Voegtli, Lance Williams & Jonathan B. Houze. (2014) Discovery of 2-Pyridylureas as Glucokinase Activators. Journal of Medicinal Chemistry 57:19, pages 8180-8186.
Crossref
Crossref
Takafumi Yamagami, Noriaki Moriyama, Masahiro Kyuhara, Atsushi Moroda, Takeshi Uemura, Hiroaki Matsumae, Yasunori Moritani & Isao Inoue. (2014) Scalable Synthesis of a Nonracemic α-Arylpropionic Acid via Ketene Desymmetrization for a Glucokinase Activator. Organic Process Research & Development 18:3, pages 437-445.
Crossref
Crossref
Zacharia S. Cheruvallath, Stephen L. GwaltneyIIII, Mark Sabat, Mingnam Tang, Jun Feng, Haixia Wang, Joanne Miura, Prasuna Guntupalli, Andy Jennings, David Hosfield, Bumsup Lee & Yiqin Wu. (2013) Design, synthesis and SAR of novel glucokinase activators. Bioorganic & Medicinal Chemistry Letters 23:7, pages 2166-2171.
Crossref
Crossref
Lei Zhang, Xiaojie Chen, Jun Liu, Qingzhang Zhu, Ying Leng, Xiaomin Luo, Hualiang Jiang & Hong Liu. (2012) Discovery of novel dual-action antidiabetic agents that inhibit glycogen phosphorylase and activate glucokinase. European Journal of Medicinal Chemistry 58, pages 624-639.
Crossref
Crossref
Jeffrey A. Pfefferkorn, Meihua Tu, Kevin J. Filipski, Angel Guzman-Perez, Jianwei Bian, Gary E. Aspnes, Matthew F. Sammons, Wei Song, Jian-Cheng Li, Christopher S. Jones, Leena Patel, Tim Rasmusson, Dongxiang Zeng, Kapil Karki, Michael Hamilton, Richard Hank, Karen Atkinson, John Litchfield, Robert Aiello, Levenia Baker, Nicole Barucci, Patricia Bourassa, Francis Bourbounais, Theresa D’Aquila, David R. Derksen, Margit MacDougall & Alan Robertson. (2012) The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of Type 2 diabetes mellitus. Bioorganic & Medicinal Chemistry Letters 22:23, pages 7100-7105.
Crossref
Crossref
Kevin J Filipski, Kentaro Futatsugi, Jeffrey A Pfefferkorn & Benjamin D Stevens. (2012) Glucokinase activators. Pharmaceutical Patent Analyst 1:3, pages 301-311.
Crossref
Crossref
Weiwei Mao, Mengmeng Ning, Zhiqing Liu, Qingzhang Zhu, Ying Leng & Ao Zhang. (2012) Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators. Bioorganic & Medicinal Chemistry 20:9, pages 2982-2991.
Crossref
Crossref
E. J. Verspohl. (2012) Novel Pharmacological Approaches to the Treatment of Type 2 Diabetes. Pharmacological Reviews 64:2, pages 188-237.
Crossref
Crossref
Jeffrey A. Pfefferkorn, Angel Guzman-Perez, John Litchfield, Robert Aiello, Judith L. Treadway, John Pettersen, Martha L. Minich, Kevin J. Filipski, Christopher S. Jones, Meihua Tu, Gary Aspnes, Hud Risley, Jianwei Bian, Benjamin D. Stevens, Patricia Bourassa, Theresa D’Aquila, Levenia Baker, Nicole Barucci, Alan S. Robertson, Francis Bourbonais, David R. Derksen, Margit MacDougall, Over Cabrera, Jing Chen, Amanda Lee Lapworth, James A. Landro, William J. Zavadoski, Karen Atkinson, Nahor Haddish-Berhane, Beijing Tan, Lili Yao, Rachel E. Kosa, Manthena V. Varma, Bo Feng, David B. Duignan, Ayman El-Kattan, Sharad Murdande, Shenping Liu, Mark Ammirati, John Knafels, Paul DaSilva-Jardine, Laurel Sweet, Spiros Liras & Timothy P. Rolph. (2012)
Discovery of (
S
)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1
H
-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus
. Journal of Medicinal Chemistry 55:3, pages 1318-1333.
Crossref
Crossref
Jun-ichi Eiki, Yasufumi Nagata, Mayumi Futamura, Kaori Sasaki-Yamamoto, Tomoharu Iino, Teruyuki Nishimura, Masato Chiba, Sumika Ohyama, Riki Yoshida-Yoshimioto, Kenji Fujii, Hideka Hosaka, Hiroko Goto-Shimazaki, Akito Kadotani, Tomoyuki Ohe, Songnian Lin, Ronald B. Langdon & Joel P. Berger. (2011) Pharmacokinetic and Pharmacodynamic Properties of the Glucokinase Activator MK-0941 in Rodent Models of Type 2 Diabetes and Healthy Dogs. Molecular Pharmacology 80:6, pages 1156-1165.
Crossref
Crossref
Martin Lang, Markus H.-J. Seifert, Kristina K. Wolf, Andrea Aschenbrenner, Roland Baumgartner, Tanja Wieber, Viola Trentinaglia, Marcus Blisse, Nobumitsu Tajima, Tokuyuki Yamashita, Daniel Vitt & Hitoshi Noda. (2011) Discovery and hit-to-lead optimization of novel allosteric glucokinase activators. Bioorganic & Medicinal Chemistry Letters 21:18, pages 5417-5422.
Crossref
Crossref
Gang Ni, Zhu-Fang Shen, Yang Lu, Ying-Hong Wang, Yan-Bo Tang, Ruo-Yun Chen, Zhi-You Hao & De-Quan Yu. (2011)
Glucokinase-Activating Sesquinlignans from the Rhizomes of
Acorus tatarinowii
Schott
. The Journal of Organic Chemistry 76:7, pages 2056-2061.
Crossref
Crossref
Jeffrey A. Pfefferkorn, Angel Guzman-Perez, Peter J. Oates, John Litchfield, Gary Aspnes, Arindrajit Basak, John Benbow, Martin A. Berliner, Jianwei Bian, Chulho Choi, Kevin Freeman-Cook, Jeffrey W. Corbett, Mary Didiuk, Joshua R. Dunetz, Kevin J. Filipski, William M. Hungerford, Christopher S. Jones, Kapil Karki, Anthony Ling, Jian-Cheng Li, Leena Patel, Christian Perreault, Hud Risley, James Saenz, Wei Song, Meihua Tu, Robert Aiello, Karen Atkinson, Nicole Barucci, David Beebe, Patricia Bourassa, Francis Bourbounais, Anne M. Brodeur, Rena Burbey, Jing Chen, Theresa D'Aquila, David R. Derksen, Nahor Haddish-Berhane, Cong Huang, James Landro, Amanda Lee Lapworth, Margit MacDougall, David Perregaux, John Pettersen, Alan Robertson, Beijing Tan, Judith L. Treadway, Shenping Liu, Xiayang Qiu, John Knafels, Mark Ammirati, Xi Song, Paul DaSilva-Jardine, Spiros Liras, Laurel Sweet & Timothy P. Rolph. (2011) Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus. MedChemComm 2:9, pages 828.
Crossref
Crossref
Zhiqing Liu, Qingzhang Zhu, Fuying Li, Lina Zhang, Ying Leng & Ao Zhang. (2011) N-(5-substituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl) propanamides as glucokinase activators. MedChemComm 2:6, pages 531.
Crossref
Crossref
Franz M. Matschinsky, Bogumil Zelent, Nicolai M. Doliba, Klaus H. Kaestner, Jane M. Vanderkooi, Joseph Grimsby, Steven J. Berthel & Ramakanth Sarabu. 2011. Diabetes - Perspectives in Drug Therapy. Diabetes - Perspectives in Drug Therapy
357
401
.
Ramakanth Sarabu, Jefferson W. Tilley & Joseph Grimsby. 2010. Accounts in Drug Discovery. Accounts in Drug Discovery
51
70
.
Nancy-Ellen Haynes, Wendy L. Corbett, Fred T. Bizzarro, Kevin R. Guertin, Darryl W. Hilliard, George W. Holland, Robert F. Kester, Paige E. Mahaney, Lida Qi, Cheryl L. Spence, John Tengi, Mark T. Dvorozniak, Aruna Railkar, Franz M. Matschinsky, Joseph F. Grippo, Joseph Grimsby & Ramakanth Sarabu. (2010)
Discovery, Structure−Activity Relationships, Pharmacokinetics, and Efficacy of Glucokinase Activator (2
R
)-3-Cyclopentyl-2-(4-methanesulfonylphenyl)-
N
-thiazol-2-yl-propionamide (RO0281675)
. Journal of Medicinal Chemistry 53:9, pages 3618-3625.
Crossref
Crossref
Malrey Lee, Thomas M. Gatton & Keun-Kwang Lee. (2010) A Monitoring and Advisory System for Diabetes Patient Management Using a Rule-Based Method and KNN. Sensors 10:4, pages 3934-3953.
Crossref
Crossref
Tomoharu Iino, Noriaki Hashimoto, Takuro Hasegawa, Masato Chiba, Jun-ichi Eiki & Teruyuki Nishimura. (2010) Metabolic activation of N-thiazol-2-yl benzamide as glucokinase activators: Impacts of glutathione trapping on covalent binding. Bioorganic & Medicinal Chemistry Letters 20:5, pages 1619-1622.
Crossref
Crossref
Gregory R. Bebernitz, Valerie Beaulieu, Bethany A. Dale, Richard Deacon, Alokesh Duttaroy, Jiaping Gao, Melissa S. Grondine, Ramesh C. Gupta, Mesut Kakmak, Michael Kavana, Louise C. Kirman, Jinsheng Liang, Wieslawa M. Maniara, Siralee Munshi, Sunil S. Nadkarni, Herbert F. Schuster, Travis Stams, Irene St. Denny, Paul M. Taslimi, Brian Vash & Shari L. Caplan. (2009) Investigation of Functionally Liver Selective Glucokinase Activators for the Treatment of Type 2 Diabetes. Journal of Medicinal Chemistry 52:19, pages 6142-6152.
Crossref
Crossref
Tomoharu Iino, Yasuhiro Sasaki, Makoto Bamba, Morihiro Mitsuya, Akio Ohno, Kenji Kamata, Hideka Hosaka, Hiroko Maruki, Mayumi Futamura, Riki Yoshimoto, Sumika Ohyama, Kaori Sasaki, Masato Chiba, Norikazu Ohtake, Yasufumi Nagata, Jun-ichi Eiki & Teruyuki Nishimura. (2009) Discovery and structure–activity relationships of a novel class of quinazoline glucokinase activators. Bioorganic & Medicinal Chemistry Letters 19:19, pages 5531-5538.
Crossref
Crossref
Keiji Takahashi, Noriaki Hashimoto, Chisato Nakama, Kenji Kamata, Kaori Sasaki, Riki Yoshimoto, Sumika Ohyama, Hideka Hosaka, Hiroko Maruki, Yasufumi Nagata, Jun-ichi Eiki & Teruyuki Nishimura. (2009) The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators. Bioorganic & Medicinal Chemistry 17:19, pages 7042-7051.
Crossref
Crossref
Manojit Pal. (2009) Recent advances in glucokinase activators for the treatment of type 2 diabetes. Drug Discovery Today 14:15-16, pages 784-792.
Crossref
Crossref
Makoto Ishikawa, Katsumasa Nonoshita, Yoshio Ogino, Yoshikazu Nagae, Daisuke Tsukahara, Hideka Hosaka, Hiroko Maruki, Sumika Ohyama, Riki Yoshimoto, Kaori Sasaki, Yasufumi Nagata, Jun-ichi Eiki & Teruyuki Nishimura. (2009) Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators. Bioorganic & Medicinal Chemistry Letters 19:15, pages 4450-4454.
Crossref
Crossref
Jeffrey A. Pfefferkorn, Jihong Lou, Martha L. Minich, Kevin J. Filipski, Mingying He, Ru Zhou, Syed Ahmed, John Benbow, Angel-Guzman Perez, Meihua Tu, John Litchfield, Raman Sharma, Karen Metzler, Francis Bourbonais, Cong Huang, David A. Beebe & Peter J. Oates. (2009) Pyridones as glucokinase activators: Identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle. Bioorganic & Medicinal Chemistry Letters 19:12, pages 3247-3252.
Crossref
Crossref
Tomoharu Iino, Noriaki Hashimoto, Kaori Sasaki, Sumika Ohyama, Riki Yoshimoto, Hideka Hosaka, Takuro Hasegawa, Masato Chiba, Yasufumi Nagata, Jun-ichi Eiki & Teruyuki Nishimura. (2009) Structure–activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy. Bioorganic & Medicinal Chemistry 17:11, pages 3800-3809.
Crossref
Crossref
Franz M. Matschinsky. (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nature Reviews Drug Discovery 8:5, pages 399-416.
Crossref
Crossref
Tomoharu Iino, Daisuke Tsukahara, Kenji Kamata, Kaori Sasaki, Sumika Ohyama, Hideka Hosaka, Takuro Hasegawa, Masato Chiba, Yasufumi Nagata, Jun-ichi Eiki & Teruyuki Nishimura. (2009) Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators. Bioorganic & Medicinal Chemistry 17:7, pages 2733-2743.
Crossref
Crossref
Teruyuki Nishimura, Tomoharu Iino, Morihiro Mitsuya, Makoto Bamba, Hitomi Watanabe, Daisuke Tsukahara, Kenji Kamata, Kaori Sasaki, Sumika Ohyama, Hideka Hosaka, Mayumi Futamura, Yasufumi Nagata & Jun-ichi Eiki. (2009) Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators. Bioorganic & Medicinal Chemistry Letters 19:5, pages 1357-1360.
Crossref
Crossref
Michael L. Mohler, Yali He, Zhongzhi Wu, Dong Jin Hwang & Duane D. Miller. (2008) Recent and emerging anti‐diabetes targets. Medicinal Research Reviews 29:1, pages 125-195.
Crossref
Crossref